DYRK1A activates NFATC1 to increase glioblastoma migration

Glioblastoma (GBM) is the most aggressive glioma, and is prone to develop resistance to chemotherapy and radiotherapy; hence, patients with glioblastoma have a high recurrence rate and a low 1‐year survival rate. In addition, the pathogenesis of glioblastoma is complex and largely unknown, and the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Heng, Sun, Qian, Chen, Shuai, Chen, Long, Jia, Wenming, Zhao, Juan, Sun, Xiulian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446559/
https://www.ncbi.nlm.nih.gov/pubmed/34309232
http://dx.doi.org/10.1002/cam4.4159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446559/
https://www.ncbi.nlm.nih.gov/pubmed/34309232
http://dx.doi.org/10.1002/cam4.4159

Ejemplares similares